Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming

Journal of Immunology

Volumn 191, Issue 12, 2013, Pages 6200-6207

  Marzec, Michal ^a   Halasa, Krzysztof ^a   Liu, Xiaobin ^a   Wang, Hong Y ^a   Cheng, Mangeng ^b   Baldwin, Donald ^a   Tobias, John W ^a   Schuster, Stephen J ^c   Woetmann, Anders ^d   Zhang, Qian ^a   Turner, Suzanne D ^e   Ødum, Niels ^d   Wasik, Mariusz A ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CEPHALON INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 2; JANUS KINASE; NUCLEOPHOSMIN; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CD25 GENE; CD4+ T LYMPHOCYTE; CELL GROWTH; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; EGR 1 GENE; FOSL 1 GENE; GENE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IRF 4 GENE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALIGNANT TRANSFORMATION; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SOCS3 GENE; T CELL LYMPHOMA;

EID: 84890416361     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300744     Document Type: Article

References (47)

1. Li, R., and S. W. Morris. 2008. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med. Res. Rev. 28: 372-412.
2. Chiarle, R., C. Voena, C. Ambrogio, R. Piva, and G. Inghirami. 2008. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8: 11-23.
3. Wasik, M. A., Q. Zhang, M. Marzec, M. Kasprzycka, H. Y. Wang, and X. Liu. 2009. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin. Oncol. 36(2, Suppl. 1)S27-S35.
4. Fujimoto, J., M. Shiota, T. Iwahara, N. Seki, H. Satoh, S. Mori, and T. Yamamoto. 1996. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl. Acad. Sci. USA 93: 4181-4186.
5. Morris, S. W., M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro, D. L. Saltman, and A. T. Look. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
6. Bischof, D., K. Pulford, D. Y. Mason, and S. W. Morris. 1997. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell. Biol. 17: 2312-2325.
7. Kuefer, M. U., A. T. Look, K. Pulford, F. G. Behm, P. K. Pattengale, D. Y. Mason, and S. W. Morris. 1997. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90: 2901-2910.
8. Chiarle, R., J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, and G. Inghirami. 2003. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101: 1919-1927.
9. Zhang, Q., P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A.Wasik. 2002. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 168: 466-474.
10. Kasprzycka, M., M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik. 2006. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA 103: 9964-9969.
11. Marzec, M., M. Kasprzycka, X. Liu, M. El-Salem, K. Halasa, P. N. Raghunath, R. Bucki, P. Wlodarski, and M. A. Wasik. 2007. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26: 5606-5614.
12. Rochman, Y., R. Spolski, and W. J. Leonard. 2009. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9: 480-490.
13. Overwijk, W. W., and K. S. Schluns. 2009. Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 132: 153-165.
14. Smith, K. A. 1980. T-cell growth factor. Immunol. Rev. 51: 337-357.
15. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240: 1169-1176.
16. Hatakeyama, M., M. Tsudo, S. Minamoto, T. Kono, T. Doi, T. Miyata, M. Miyasaka, and T. Taniguchi. 1989. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science 244: 551-556.
17. Smith, K. A. 1992. Interleukin-2. Curr. Opin. Immunol. 4: 271-276.
18. Bessoles, S., F. Fouret, S. Dudal, G. S. Besra, F. Sanchez, and V. Lafont. 2008. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J. Leukoc. Biol. 84: 224-233.
19. Mitchell, T. J., and S. John. 2005. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114: 301-312.
20. Evans, G. A., O. M. Howard, R. Erwin, and W. L. Farrar. 1993. Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck. Biochem. J. 294: 339-342.
21. Friedmann, M. C., T. S. Migone, S. M. Russell, and W. J. Leonard. 1996. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc. Natl. Acad. Sci. USA 93: 2077-2082.
22. Zhang, Q., I. Nowak, E. C. Vonderheid, A. H. Rook, M. E. Kadin, P. C. Nowell, L. M. Shaw, and M. A.Wasik. 1996. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA 93: 9148-9153.
23. Ravichandran, K. S., V. Igras, S. E. Shoelson, S. W. Fesik, and S. J. Burakoff. 1996. Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling. Proc. Natl. Acad. Sci. USA 93: 5275-5280.
24. Gaffen, S. L., S. Y. Lai, M. Ha, X. Liu, L. Hennighausen, W. C. Greene, and M. A. Goldsmith. 1996. Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. J. Biol. Chem. 271: 21381-21390.
25. Fujii, H., K. Ogasawara, H. Otsuka, M. Suzuki, K. Yamamura, T. Yokochi, T. Miyazaki, H. Suzuki, T. W. Mak, S. Taki, and T. Taniguchi. 1998. Functional dissection of the cytoplasmic subregions of the IL-2 receptor betac chain in primary lymphocyte populations. EMBO J. 17: 6551-6557.
26. Gadina, M., C. Sudarshan, R. Visconti, Y. J. Zhou, H. Gu, B. G. Neel, and J. J. O'Shea. 2000. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J. Biol. Chem. 275: 26959-26966.
27. Bensinger, S. J., P. T. Walsh, J. Zhang, M. Carroll, R. Parsons, J. C. Rathmell, C. B. Thompson, M. A. Burchill, M. A. Farrar, and L. A. Turka. 2004. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J. Immunol. 172: 5287-5296.
28. Marzec, M., M. Kasprzycka, A. Ptasznik, P. Wlodarski, Q. Zhang, N. Odum, and M. A. Wasik. 2005. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 85: 1544-1554.
29. Marzec, M., M. Kasprzycka, X. Liu, P. N. Raghunath, P. Wlodarski, and M. A. Wasik. 2007. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26: 813-821.
30. Marzec, M., K. Halasa, M. Kasprzycka, M. Wysocka, X. Liu, J. W. Tobias, D. Baldwin, Q. Zhang, N. Odum, A. H. Rook, and M. A. Wasik. 2008. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res. 68: 1083-1091.
31. Gery, S., and H. P. Koeffler. 2010. Circadian rhythms and cancer. Cell Cycle 9: 1097-1103.
32. Cui, Y. X., A. Kerby, F. K. McDuff, H. Ye, and S. D. Turner. 2009. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 113: 5217-5227.
33. Nakajima, H., X. W. Liu, A. Wynshaw-Boris, L. A. Rosenthal, K. Imada, D. S. Finbloom, L. Hennighausen, and W. J. Leonard. 1997. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 7: 691-701.
34. Kim, H. P., J. Kelly, and W. J. Leonard. 2001. The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 15: 159-172.
35. Zhang, Q., H. Y. Wang, X. Liu, and M. A. Wasik. 2007. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13: 1341-1348.
36. Nieborowska-Skorska, M., A. Slupianek, L. Xue, Q. Zhang, P. N. Raghunath, G. Hoser, M. A. Wasik, S. W. Morris, and T. Skorski. 2001. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 61: 6517-6523.
37. Gitenay, D., and V. T. Baron. 2009. Is EGR1 a potential target for prostate cancer therapy? Future Oncol. 5: 993-1003.
38. Decker, E. L., N. Nehmann, E. Kampen, H. Eibel, P. F. Zipfel, and C. Skerka. 2003. Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acids Res. 31: 911-921.
39. Zhang, Q., H. Y. Wang, X. Liu, G. Bhutani, K. Kantekure, and M. Wasik. 2011. IL-2R common gamma-chain is epigenetically silenced by nucleophosphinanaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc. Natl. Acad. Sci. USA 108: 11977-11982.
40. Turner, S. D., D. Yeung, K. Hadfield, S. J. Cook, and D. R. Alexander. 2007. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell. Signal. 19: 740-747.
41. Ambrogio, C., C. Martinengo, C. Voena, F. Tondat, L. Riera, P. F. di Celle, G. Inghirami, and R. Chiarle. 2009. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 69: 8611-8619.
42. Mahalingam, D., A. Natoni, M. Keane, A. Samali, and E. Szegezdi. 2010. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br. J. Cancer 102: 754-764.
43. Abraham, R. M., Q. Zhang, N. Odum, and M. A. Wasik. 2011. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol. Ther. 12: 1019-1022.
44. Takemoto, S., J. C. Mulloy, A. Cereseto, T. S. Migone, B. K. Patel, M. Matsuoka, K. Yamaguchi, K. Takatsuki, S. Kamihira, J. D. White, et al. 1997. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 94: 13897-13902.
45. Elliott, N. E., S. M. Cleveland, V. Grann, J. Janik, T. A. Waldmann, and U. P. Davé. 2011. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 118: 3911-3921.
46. Koo, G. C., S. Y. Tan, T. Tang, S. L. Poon, G. E. Allen, L. Tan, S. C. Chong, W. S. Ong, K. Tay, M. Tao, et al. 2012. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2: 591-597.
47. Gambacorti-Passerini, C., C. Messa, and E. M. Pogliani. 2011. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364: 775-776.